These two favorites are each focused on new biotech drug development projects.
Biogen Idec, Pfizer, Bristol-Myers and Celgene are among companies awaiting US approval of key treatments.
The failure raises more questions about treatments designed to raise good cholesterol levels.
The biotech's partner says the vaccine didn't meet a study goal to show effectiveness. Stock drops almost 60%.
This biotech company's Soliris drug shows promise in treating several rare, life threatening diseases.
Analysts expect pomalidomide will win US approval in February, adding a potential blockbuster treatment to the biotech's drug lineup.
These stocks are supported by both solid fundamentals and strong technical positions.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
Inexpensive small caps are a time-tested group of performers. Here are several that could rank among next year's biggest winners.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.